CN110964672B - 戊糖片球菌ccfm1104、其发酵食品及应用 - Google Patents
戊糖片球菌ccfm1104、其发酵食品及应用 Download PDFInfo
- Publication number
- CN110964672B CN110964672B CN201911386349.2A CN201911386349A CN110964672B CN 110964672 B CN110964672 B CN 110964672B CN 201911386349 A CN201911386349 A CN 201911386349A CN 110964672 B CN110964672 B CN 110964672B
- Authority
- CN
- China
- Prior art keywords
- pfos
- ccfm1104
- pediococcus pentosaceus
- liver
- capacity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000191996 Pediococcus pentosaceus Species 0.000 title claims abstract description 64
- 235000021107 fermented food Nutrition 0.000 title claims description 17
- YFSUTJLHUFNCNZ-UHFFFAOYSA-N perfluorooctane-1-sulfonic acid Chemical compound OS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F YFSUTJLHUFNCNZ-UHFFFAOYSA-N 0.000 claims abstract description 88
- 208000019423 liver disease Diseases 0.000 claims abstract description 11
- 235000013305 food Nutrition 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 6
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 7
- 235000013365 dairy product Nutrition 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 5
- 240000007087 Apium graveolens Species 0.000 claims description 3
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims description 3
- 235000010591 Appio Nutrition 0.000 claims description 3
- 235000016068 Berberis vulgaris Nutrition 0.000 claims description 3
- 241000335053 Beta vulgaris Species 0.000 claims description 3
- 240000007124 Brassica oleracea Species 0.000 claims description 3
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 3
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims description 3
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 claims description 3
- 240000008067 Cucumis sativus Species 0.000 claims description 3
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims description 3
- 244000000626 Daucus carota Species 0.000 claims description 3
- 235000002767 Daucus carota Nutrition 0.000 claims description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 3
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 3
- 235000013351 cheese Nutrition 0.000 claims description 3
- 235000015142 cultured sour cream Nutrition 0.000 claims description 3
- 235000021056 liquid food Nutrition 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 235000021055 solid food Nutrition 0.000 claims description 3
- 231100000331 toxic Toxicity 0.000 claims description 3
- 230000002588 toxic effect Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims 2
- 230000004151 fermentation Effects 0.000 claims 2
- 210000004185 liver Anatomy 0.000 abstract description 32
- 230000000968 intestinal effect Effects 0.000 abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 238000001179 sorption measurement Methods 0.000 abstract description 13
- 206010020772 Hypertension Diseases 0.000 abstract description 11
- 208000008589 Obesity Diseases 0.000 abstract description 11
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 11
- 235000020824 obesity Nutrition 0.000 abstract description 11
- 230000003078 antioxidant effect Effects 0.000 abstract description 10
- 230000001603 reducing effect Effects 0.000 abstract description 10
- 206010019842 Hepatomegaly Diseases 0.000 abstract description 9
- 239000003963 antioxidant agent Substances 0.000 abstract description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 8
- 208000035475 disorder Diseases 0.000 abstract description 8
- 231100000419 toxicity Toxicity 0.000 abstract description 8
- 230000001988 toxicity Effects 0.000 abstract description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 7
- 238000000338 in vitro Methods 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 3
- GBYHQDUKBHZVSI-UHFFFAOYSA-N N-(dinitroamino)-N-(2,3-diphenylphenyl)nitramide Chemical compound C1(=CC=CC=C1)C=1C(=C(C=CC1)N(N([N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-])C1=CC=CC=C1 GBYHQDUKBHZVSI-UHFFFAOYSA-N 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 26
- 241000186660 Lactobacillus Species 0.000 description 21
- 229940039696 lactobacillus Drugs 0.000 description 21
- 241000186000 Bifidobacterium Species 0.000 description 20
- -1 perfluoro compound Chemical class 0.000 description 20
- 241000160321 Parabacteroides Species 0.000 description 19
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 15
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 14
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 14
- 108010082126 Alanine transaminase Proteins 0.000 description 13
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000004310 lactic acid Substances 0.000 description 9
- 235000014655 lactic acid Nutrition 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 241000606125 Bacteroides Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001052560 Thallis Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 238000004807 desolvation Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000003794 Gram staining Methods 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- ZFRKQXVRDFCRJG-UHFFFAOYSA-N skatole Chemical compound C1=CC=C2C(C)=CNC2=C1 ZFRKQXVRDFCRJG-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000174681 Michelia champaca Species 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- DZKZCXUIXLRBSY-UHFFFAOYSA-N Oc1ccc2oc(O)c(-c3ccccc3)c(=O)c2c1O Chemical compound Oc1ccc2oc(O)c(-c3ccccc3)c(=O)c2c1O DZKZCXUIXLRBSY-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 206010074268 Reproductive toxicity Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000007673 developmental toxicity Effects 0.000 description 1
- 231100000415 developmental toxicity Toxicity 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000009123 feedback regulation Effects 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 102000054999 human core Human genes 0.000 description 1
- 108700026469 human core Proteins 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007688 immunotoxicity Effects 0.000 description 1
- 231100000386 immunotoxicity Toxicity 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000009125 negative feedback regulation Effects 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000007696 reproductive toxicity Effects 0.000 description 1
- 231100000372 reproductive toxicity Toxicity 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940074386 skatole Drugs 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C11/00—Milk substitutes, e.g. coffee whitener compositions
- A23C11/02—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins
- A23C11/10—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing or not lactose but no other milk components as source of fats, carbohydrates or proteins
- A23C11/103—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing or not lactose but no other milk components as source of fats, carbohydrates or proteins containing only proteins from pulses, oilseeds or nuts, e.g. nut milk
- A23C11/106—Addition of, or treatment with, microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/41—Pediococcus
- A23V2400/427—Pentosaceus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
Abstract
本发明公开了戊糖片球菌CCFM1104、其发酵食品及应用,戊糖片球菌CCFM1104在体外对PFOS具有很好地吸附能力以降低PFOS浓度、具良好的清除二苯基三硝基苯肼自由基,清除羟自由基的能力和还原能力,改善因PFOS暴露造成的肝脏肿大,降低肝脏中TNF‑α的含量,提高CAT、SOD及抗氧化能力的水平,改善肠道菌群紊乱,降低肝病、高血压、糖尿病和肥胖等疾病的发生倾向。戊糖片球菌CCFM1104可用于制备具有缓解PFOS毒性的食品、保健品和药品,具有非常广泛的应用前景。
Description
技术领域
本发明属于微生物技术领域,具体涉及戊糖片球菌CCFM1104、其发酵食品及应用。
背景技术
全氟化合物由于其疏水疏油特性,并且具有良好的热稳定性,化学稳定性和生物稳定性,在各行各业受到了广泛的应用。用于成衣(如防水,防污户外服饰)及家居纺织品(如地毯,家具布料等),外卖食品容器,个人护理产品(如牙线)以及灭火泡沫等等。而其中PFOS作为是多种氟类化合物的最终转化产物之一,可通过环境暴露,从而直接对人体造成危害,或是进入动植物体内通过食物链在人体内生物累积,因此受到了研究学者越来越多的重视。尽管早在20世纪60年代,PFOS就被看作是潜在污染物,但一直到21世纪,PFOS在人体血液和生物体内被检出,才受到人们的广泛关注,并逐步展开有关方面的研究。人们逐渐意识到PFOS的毒性和危害,因此一系列措施使得PFOS的生产和使用被逐步限制。然而,在部分国家PFOS仍在大量使用,且环境中残留的PFOS还会在未来很长一段时间对整个生态系统造成持久影响。
暴露人群血液中PFOS含量与可能的健康影响之间的关联研究发现,暴露于PFOS可能与血液中总胆固醇浓度的升高,血糖升高、血脂升高及肝酶ALT和ALP浓度上升与体重降低有较明显的关系。这些迹象表明,PFOS可能会影响人体的肝脏功能,脂代谢与免疫功能。而在人体中出现的影响在哺乳动物体内已经被明确发现,PFOS具有肝脏毒性,免疫毒性,生殖毒性,发育毒性,神经毒性等多种毒性作用。PFOS可以导致肝肿大,同时可诱发肝组织氧化应激,使自由基异常增多,可能是造成肝脏损伤的主要原因。PFOS暴露对水生动物和啮齿动物免疫系统的多个免疫器官均产生不同程度的损伤,造成免疫器官脾脏和胸腺的萎缩老化,明显干扰斑马鱼脾脏白介素的表达,淋巴细胞的凋亡与衰退。在对小鼠的暴露实验中,高剂量PFOS暴露降低小鼠T淋巴细胞和B淋巴细胞的增值功能,显著诱导小鼠肝水肿变性和空泡形成,降低胆汁酸含量,PFOS可介导星形胶质细胞中的JAK2/STAT3通路,导致TNF-α分泌异常引起神经毒性干扰雌激素和雄激素稳态从而影响生长发育。
目前缓解PFOS毒性的方法多是从具有高抗氧化活性的天然化学物质着手,研究中有缓解作用的如槲皮素、枸杞多糖、桑色素、三羟异黄酮、番茄红素等。但这些天然物质都存在价格昂贵且难以获得,此外由于人体的承受能力,大量的摄入对人体是否存在的潜在危害尚不得知。因此,寻找一种能够有效缓解PFOS毒性,并且对人体不存在其他可能有害作用的有效方法显然十分有必要。
发明内容
本部分的目的在于概述本发明的实施例的一些方面以及简要介绍一些较佳实施例。在本部分以及本申请的说明书摘要和发明名称中可能会做些简化或省略以避免使本部分、说明书摘要和发明名称的目的模糊,而这种简化或省略不能用于限制本发明的范围。
作为本发明其中一个方面,本发明克服现有技术中存在的不足,提供戊糖片球菌CCFM1104,保藏编号为GDMCC No:60898。
作为本发明的另一个方面,本发明克服现有技术中存在的不足,提供一种发酵食品:所述发酵食品为使用戊糖片球菌CCFM1104发酵生产制得,所述发酵食品包括固态食品、液态食品、半固态食品。
作为本发明所述的发酵食品的一种优选方案:所述发酵食品包括乳制品、豆制品、果蔬制品,所述乳制品包括牛奶、酸奶油、奶酪;所述果蔬制品包括黄瓜、胡萝卜、甜菜、芹菜、圆白菜制品。
作为本发明的另一个方面,本发明克服现有技术中存在的不足,提供戊糖片球菌CCFM1104在制备体内非定植益生菌中的应用。
作为本发明的另一个方面,本发明克服现有技术中存在的不足,提供戊糖片球菌CCFM1104在制备缓解PFOS的毒性作用,抗肝病、抗高血压、抗糖尿病、抗肥胖等的药物和保健品中的应用。
作为本发明所述的应用的一种优选方案:所述戊糖片球菌CCFM1104在体外对PFOS具有很好地吸附能力以降低PFOS浓度、具良好的清除二苯基三硝基苯肼自由基(DPPH),清除羟自由基的能力和还原能力,改善因PFOS暴露造成的肝脏肿大,降低肝脏中TNF-α的含量,降低血清中谷丙转氨酶(ALT)、谷草转氨酶(AST)、碱性磷酸酶(ALP)的含量,提高CAT、SOD及抗氧化能力的水平,改善肠道菌群紊乱,降低肠道中S24-7科、乳酸杆菌属(Lactobacillus)、双歧杆菌属(Bifidobacterium)和副拟杆菌(Parabacteroides)的丰度,降低肝病、高血压、糖尿病和肥胖等疾病的发生倾向。
作为本发明的另一个方面,本发明克服现有技术中存在的不足,提供所述的发酵食品在制品缓解PFOS毒性性、抗肝病、抗高血压、抗糖尿病、抗肥胖的功能性食品中的应用。
本发明的有益效果:本发明所述戊糖片球菌CCFM1104在体外对PFOS具有很好地吸附能力以降低PFOS浓度、具良好的清除二苯基三硝基苯肼自由基(DPPH),清除羟自由基的能力和还原能力,改善因PFOS暴露造成的肝脏肿大,降低肝脏中TNF-α的含量,降低血清中谷丙转氨酶(ALT)、谷草转氨酶(AST)、碱性磷酸酶(ALP)的含量,提高CAT、SOD及抗氧化能力的水平,改善肠道菌群紊乱,降低肠道中S24-7科、乳酸杆菌属(Lactobacillus)、双歧杆菌属(Bifidobacterium)和副拟杆菌(Parabacteroides)的丰度,降低肝病、高血压、糖尿病和肥胖等疾病的发生倾向。戊糖片球菌CCFM1104能够用于制备具有缓解PFOS毒性的食品、保健品和药品,具有非常广泛的应用前景。
附图说明
为了更清楚地说明本发明实施例的技术方案,下面将对实施例描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动性的前提下,还可以根据这些附图获得其它的附图。其中:
图1为本发明菌株在体外重悬于浓度为20mg/L PFOS中经过37℃,200rpm摇床12h后,过0.22μm水系滤膜进入超高效液相色谱质谱联用仪中,吸附后PFOS浓度变化示意图。
图2为本发明菌株在体外清除二苯基三硝基苯肼自由基(DPPH)能力,清除羟自由基能力、还原能力。
图3为本发明菌株干预15天后小鼠暴露于PFOS,小鼠肝脏比重的变化图。其中不同字母代表具有显著差异。
图4为本发明菌株干预15天后小鼠暴露于PFOS,小鼠血清中ALP、ALT、AST水平示意图。其中不同字母代表具有显著差异。
图5为本发明菌株干预15天后暴露于PFOS,小鼠肝脏中CAT、SOD及抗氧化能力的变化示意图。其中不同字母代表具有显著差异。
图6为本发明菌株干预15天后小鼠暴露于PFOS,小鼠肝脏中肿瘤坏死因子α示意图。其中不同字母代表具有显著差异。
图7为本发明菌株干预15天后小鼠暴露于PFOS,小鼠肠道菌群α多样性变化示意图;其中不同字母代表具有显著差异。
图8为本发明菌株干预15天后小鼠暴露于PFOS,小鼠肠道中S24-7科、乳酸杆菌属(Lactobacillus)、双歧杆菌属(Bifidobacterium)和副拟杆菌(Parabacteroides)的丰度的变化示意图;其中不同字母代表具有显著差异。
具体实施方式
为使本发明的上述目的、特征和优点能够更加明显易懂,下面结合具体实施例对本发明的具体实施方式做详细的说明。
在下面的描述中阐述了很多具体细节以便于充分理解本发明,但是本发明还可以采用其他不同于在此描述的其它方式来实施,本领域技术人员可以在不违背本发明内涵的情况下做类似推广,因此本发明不受下面公开的具体实施例的限制。
其次,此处所称的“一个实施例”或“实施例”是指可包含于本发明至少一个实现方式中的特定特征、结构或特性。在本说明书中不同地方出现的“在一个实施例中”并非均指同一个实施例,也不是单独的或选择性的与其他实施例互相排斥的实施例。
本发明的戊糖片球菌(Pediococcus pentosaceus)CCFM1104,于2019年11月22日保藏于广东省微生物菌种保藏中心,保藏地址为广州市先烈中路100号大院59号楼5楼,广东省微生物研究所,保藏编号为GDMCC No:60898。
所述戊糖片球菌具有以下生物学特性:
(1)菌体特征:革兰氏阳性,细胞球状,直径0.8~1.0μm,无鞭毛,无芽孢;
(2)菌落特征:菌落乳白色,边缘整齐,圆形,凸起,不透明,表面湿润光滑;
(3)生长特性:该菌株的最低生长温度为15℃,最高生长温度为45℃,在温度35-37℃下生长最佳,最适生长pH为6.5,培养18h后进入稳定期;
(5)体外具有良好的清除二苯基三硝基苯肼自由基(DPPH)能力,清除羟自由基能力和还原能力;
(6)戊糖片球菌CCFM1104能显著改善PFOS暴露后的肝脏肿大;
(7)戊糖片球菌CCFM1104能显著降低PFOS暴露后血清中ALP、ALT、AST的水平;
(8)戊糖片球菌CCFM1104能显著提高PFOS暴露后肝脏中CAT、SOD和抗氧化能力的水平。
(9)戊糖片球菌CCFM1104能够显著降低PFOS暴露后(10)戊糖片球菌CCFM1104显著降低肠道中S24-7科、乳酸杆菌属(Lactobacillus)、双歧杆菌属(Bifidobacterium)和副拟杆菌(Parabacteroides)的丰度,改善PFOS暴露造成的肠道菌群紊乱,降低肝病、高血压、糖尿病和肥胖等疾病的发生倾向。
所述戊糖片球菌CCFM1104的提取方法为:
(一)乳酸菌的分离筛选:
(l)收集若干份健康成人的粪便样本,将样品在含有山梨醇GM17培养基中35℃富集12h;
(2)将富集样品进行梯度稀释后涂布于添加了0.02%嗅甲酚紫的GM17固体平板上,培养24-48h;
(3)选取变色圈明显,并且符合乳酸菌目基本形态的单菌落进行平板划线纯化,筛选分离出乳酸菌;
(4)将上述单菌落培养于液体GM17培养液中培养24h后进行革兰氏染色,选取革兰氏阳性菌进行后续试验。
(二)乳酸菌的初步鉴定:溶钙圈测定法
(l)将步骤(一)所筛选得到的乳酸菌在液体山梨醇GM17培养液中培养24h,然后取l mL培养物8000rpm离心2min;
(2)用0.05M KH2PO4溶液洗涤两次;
(3)将所得菌泥重悬,划线在山梨醇GM17-0.75%CaCO3的固体培养基上,培养24h;
(4)选取溶钙圈明显,且呈凸面圆形、细密色白、无菌丝体的菌落,革兰氏染色后显微镜观察菌体为球状即初步判定为球菌。
(三)乳酸菌的分子生物学鉴定:
(l)单菌基因组抽提:
A.将步骤(二)所筛选得到的乳酸菌培养过夜,取培养过夜的菌悬液l mL于1.5mL离心管,10000rpm离心2min,弃上清得菌体;
B.用l mL无菌水吹洗菌体后,10000rpm离心2min,弃上清得菌体;
C.加入200μLSDS裂解液,80℃水浴30min;
D.加入酚-氯仿溶液200μL于菌体裂解液中,其中酚-氯仿溶液的组成成分及体积比为Tris饱和酚:氯仿:异戊醇=25:24:1,颠倒混匀后,12000rpm离心5-10min,取上清200μL;
E.加入400μL冰乙醇或冰异丙醇于200uL上清中,﹣20℃静置1h,12000rpm离心5-10min,弃上清;
F.加入500μL70%(体积百分数)冰乙醇重悬沉淀,12000rpm离心1-3min,弃上清;
G.60℃烘箱烘干,或者自然晾干;
H.50μLddH2O重溶沉淀以备PCR;
(2)16S rDNA PCR
A.细菌16S rDNA 50μLPCR反应体系:
10×Taq buffer,5μL;dNTP,5μL;27F,0.5μL;1492R,0.5μL;Taq酶,0.5μL;模板,0.5μL;ddH2O,38μL。
B.PCR条件:
95℃5min;95℃10s;55℃30s;72℃30s;step2-4 30×;72℃5min;12℃2min;
(3)制备1%琼脂糖凝胶,之后将PCR产物与10000×loading buffer混合,上样量5μL,120V跑30min,然后进行凝胶成像;
(4)将16S rDNA的PCR产物进行测序分析,将得到的序列结果使用BLAST在GeneBank中进行搜索和相似性比对,选取测序结果鉴定为属于戊糖片球菌的一种新发现的菌株,-80℃保藏备用。
实施例1:戊糖片球菌CCFM1104具有良好的PFOS吸附能力
菌体吸附对戊糖片球菌CCFM1104进行纯化和活化培养,按1%(v/v)接种量接种于MRS液体培养基中,37℃培养12h。然后在8000r/min离心5min收集菌体,取沉淀用生理盐水清理后继续在8000r/min离心5min,去沉淀得到活菌体细胞,即湿菌体。将湿菌体重悬于20mg/L PFOS溶液中,并使最终菌体浓度达到1g干菌体/L(将湿菌体重悬于不含PFOS的超纯水中作为空白对照)。使用0.1M的NaOH或HCl溶液将含菌液的PFOS溶液的pH迅速调整至3.0,添加少量的NaOH或HCl(少于0.5ml)其离子强度对PFOS吸附的影响可以忽略。随后将装有100ml样液的250ml锥形瓶置于37℃、200rpm摇床培养,12h后取样测定,2次平行试验取平均值。
PFOS吸附量的测定:吸附实验后,样液在8000r/min离心5min,并用0.22μm的水膜过滤,PFOS浓度用具有Waters SYNAPT MS系统的UPLC-MS测定,采用Acquity UPLC BEH c18柱(2.1×100mm,1.7μm,Waters Co.),柱温35℃,进样量1μL。用100%(v/v)的乙腈溶液(溶液A)和0.1%(v/v)甲酸水溶液(溶液B)作为洗脱液,进行梯度清洗,流速是0.3mL/min。
表1梯度洗脱条件
t/min | 0-0.5 | 0.5-5.0 | 5.0-7.0 | 7.0-7.5 |
溶剂A比例 | 70% | 70-100% | 100% | 100-70% |
质谱条件:电离源为ESI源;MRM检测;MS+检测;Capillary(毛细管);3.0kV;Conc(椎体):40.00V;Source Temperature(放射源温度):120℃;Desolvation(去溶剂化)温度:400℃;Conc Gas Flow:50L/h;Desolvation Gas Flow:700L/h.气体流速为0.1ml/min;质子比扫描范围:100-2000;扫面时间1s,间隔0.061s。结果用MassLynxV4.1(Waters公司)分析;根据吸附前后PFOS的浓度差异计算乳酸菌对PFOS的吸附量。测定结果列于图1,CCFM1104对20mg/L的PFOS的吸附率最高达到76.47%(69.67%±6.8%)。
实施例2:戊糖片球菌CCFM1104体外具有良好的清除二苯基三硝基苯肼自由基(DPPH)能力,清除羟自由基能力和还原能力;
将1mL戊糖片球菌CCFM1104完整细胞悬液与1mL新鲜配制的DPPH无水乙醇溶液(0.2mmol/L)充分混匀后,37℃条件下避光反应30min。将DPPH与PBS(pH7.2)混合作为对照样品,同样条件培养。7000×g离心10min后,在517nm测定吸光度,并按照以下公式计算乳酸菌清除DPPH自由基的能力:
DPPH自由基清除率(%)=[1-A517(样品)/A517(对照)]×100%。
将1mL1,10-邻二氮菲1mLPBS(pH7.2),1mL戊糖片球菌CCFM1104完整细胞悬液或以及1mLFeSO4混合均匀(称为“混合物1”)。向“混合物1”中加入1mLH2O2,37℃条件下水浴1.5h,在536nm测定吸光度,表示为A536(样品)。将“混合物1”中的完整细胞悬液换成同体积的蒸馏水,以同样条件培养并检测,表示为A536(空白)。将向“混合物1”加入的H2O2换成同体积的蒸馏水,以同样条件培养并检测,表示为A536(对照)。按照以下公式计算乳酸菌清除羟自由基的能力:
羟自由基清除率(%)=[A536(样品)-A536(空白)]/[A536(对照)-A536(空白)]×100%
将0.5mL戊糖片球菌CCFM1104完整细胞悬液与同体积的铁氰化钾(1%)及PBS缓冲液(pH6.6)混合,振荡使体系均匀。将蒸馏水与铁氰化钾及PBS混合作为空白对照。混合体系在50℃条件下培养20min,快速冷却,并加入0.5mL10%的三氯乙酸。在2000×g离心5min后,取1mL上清与1mL0.1%的氯化铁混合并反应10min。随后在700nm波长下测定吸光度,并使用半胱氨酸(Cysteine)作为表征还原力的标准。实验结果见图2。
实施例3:戊糖片球菌CCFM1104能显著改善PFOS暴露小鼠肝脏肿大6周龄雄性C57BL/6J小鼠24只,适应环境一周后,根据体重随机分为四组:空白对照组、模型组、槲皮素干预组、戊糖片球菌CCFM1104干预组,每组含6只小鼠,动物分组及处理方法见表2。
表2动物实验分组及处理方法
实施例2中的小鼠于第31天称体重,随后安乐处死,眼眶取血,取出肝脏称湿重以计算脏器系数,按以下公式计算小鼠肝脏的脏器系数:
肝脏脏器系数=肝脏湿重(g)/安乐死前小鼠体重(100g)
实验结果如图3所示,结果表明服用戊糖片球菌CCFM1104能够显著缓解由于PFOS暴露造成的小鼠肝脏肿大。
实施例4:戊糖片球菌CCFM1104能显著降低PFOS暴露小鼠血清中ALT、ALP和AST的水平
取实施例3中的血液,静置一小时后,3500r/min,离心15min,取血清待测。采用全自动生化分析仪检测血清中ALT、ALP和AST的含量。ALT、AST作为肝细胞胞质和线粒体中的非特异性功能酶,当肝细胞被破坏时会释放到血液中。ALP一般由肝脏排泄,当肝脏出现损伤时ALP可经淋巴道和肝窦进入血液。实验结果表明(图4),服用戊糖片球菌CCFM1104能够显著降低PFOS暴露小鼠血清中ALT、ALP和AST的含量。表明服用戊糖片球菌CCFM1104能够显著缓解PFOS造成的小鼠肝细胞膜结构和功能的损伤。
实施例5:戊糖片球菌CCFM1104能显著降低PFOS暴露小鼠肝脏中MDA和GSH的水平
取实施例3中的小鼠肝脏制成10%匀浆,准确称取肝脏按重量(g):体积(ml)=1:9的比例,加入9倍体积的生理盐水,冰水浴条件下机械匀浆,充分破碎细胞,5000r/min,离心10分钟,取上清测定。肝脏中SOD、CAT、和抗氧化能力T-AOC的水平根据南京建成试剂盒提供的试剂盒进行测定。CAT主要存在于过氧化物酶体中,负责H2O2的还原和细胞膜中不饱和脂肪酸的氧化保护。SOD是体内重要的抗氧化酶,对ROS具有重要的清除作用。抗氧化能力可以表明机体对待氧化应激的水平。实验结果表明(图5),服用戊糖片球菌CCFM1104能够显著提高PFOS暴露小鼠肝脏中CAT、SOD及抗氧化能力的水平。说明戊糖片球菌CCFM1104对PFOS造成的肝脏氧化应激损伤能起到有效的改善效果。
实施例6:戊糖片球菌CCFM1104能够显著降低PFOS暴露小鼠肝脏中TNF-α的含量
取实施例3中的小鼠肝脏制成10%匀浆,准确称取肝脏按重量(g):体积(ml)=1:9的比例,加入9倍体积的生理盐水,冰水浴条件下机械匀浆,充分破碎细胞,5000r/min,离心10分钟,取上清肝脏匀浆测定。肝脏中的细胞因子TNF-α含量按照ELISA试剂盒(RD)说明书测定细胞因子含量。实验结果表明服用戊糖片球菌CCFM1104能显著改善PFOS暴露造成的小鼠肝脏炎症损伤(图6)。
实施例7:戊糖片球菌CCFM1104能显著降低PFOS暴露小鼠肠道中S24-7科、乳酸杆菌属(Lactobacillus)、双歧杆菌属(Bifidobacterium)和副拟杆菌(Parabacteroides)的丰度,改善PFOS暴露造成的肠道紊乱,降低肝病、高血压、糖尿病和肥胖等疾病发生的倾向。
取实施例3中小鼠第31天的新鲜粪便,采用MP的粪便试剂盒提取小鼠粪便样品中总DNA。具体操作步骤如下主要参照试剂盒说明书进行。以小鼠粪便基因组为模板,以上游引物520F(5′-AYTGGGYDTAAAGNG-3′)、下游引物802R(5′-TACNVGGGTATCTAATCC-3′)为引物扩增16S rDNA的V3-V4区片段,目的片段长度为247bp左右。PCR反应结束,将观察到目的条带的所有PCR样品再次进行电泳,配制2.0%琼脂糖凝胶,于120V条件下电泳40min,跑胶结束后,在紫外灯下快速进行目的条带的切割。按照QIAquick Gel Extraction Kit胶回收试剂盒说明书进行目的条带胶回收。根据Qubit DNA3.0试剂盒检测样品DNA浓度,随后根据TurSeq DNA LT Sample Preparation Kit及其说明构建文库,最后根据MiSeq Regent Kit及其说明经过Illumina Miseq测序仪上机测定。测序完成后,剔除掉序列长度<200bp、引物序列、不能拼接的单序列,按照重叠碱基>10bp且无错配的标准拼接序列。将相似度大于97%序列定义为一个分类单元(Operational Taxonomic Unit,OTU),通过RibosomalDatabase Project(RDP)Bayesclassifier来确定物种。计算样品的α-多样性、β-多样性,用来评估样品的菌群多样性。其中α-多样性用chao1和observed species指数来表征,结果(图7)显示模型组小鼠的肠道菌群α多样性升高,说明PFOS暴露会伴随着一定程度的肠道紊乱。服用戊糖片球菌CCFM1104能明显降低肠道菌群的α多样性,改善肠道紊乱情况。
在PFOS染毒后,粪便中S24-7科、乳酸杆菌属(Lactobacillus)、双歧杆菌属(Bifidobacterium)和副拟杆菌(Parabacteroides)的丰度提高,而服用戊糖片球菌CCFM11104还能显著降低PFOS染毒后S24-7科、乳酸杆菌属(Lactobacillus)、双歧杆菌属(Bifidobacterium)和副拟杆菌(Parabacteroides)的丰度(图8);S24-7高度定位于恒温动物的胃肠道,革兰氏阴性非运动型厌氧型微生物,能够发酵多种碳水化合物,和非酒精性脂肪肝和高血压的发生发展有关。乳酸杆菌(Lactobacillus)是正常胃肠道和泌尿生殖器的一部分,是常见的益生菌,在乳酸菌预防实验中PFOS模型组和染毒模型出现丰度上升的情况,乳酸菌可能在PFOS暴露后出现了负反馈调节的现象。双歧杆菌(Bifidobacterium)广泛存在于人和动物的消化道、阴道和口腔等生境中,人和动物肠道菌群的重要组成成员之一,可作为益生菌而用在食品、医药和饲料方面。在正常情况下,人体内的肠道微生物形成了一个相对平衡的状态。小鼠在PFOS染毒后,肠道微生物平衡受到破坏,导致肠道菌群紊乱,某些肠道微生物如产气荚膜梭菌等在肠道中过度增殖并产生氨、胺类、硫化氢、粪臭素、吲哚、亚硝酸盐、细菌毒素等有害物质,从而进一步影响健康状况。此时,双歧杆菌(Bifidobacterium)则会产生反馈调节,丰度增多来能抑制有害细菌的生长,抵抗外来污染物的感染,合成人体需要的维生素,促进人体对矿物质的吸收,产生醋酸、丙酸、丁酸和乳酸等有机酸刺激肠道蠕动,促进排便,防止便秘以及抑制肠道腐败作用、净化肠道环境、分解致癌物质、刺激人体免疫系统,从而提高抗病能力等。副拟杆菌(Parabacteroides)是人体核心菌群之一,通过体内外实验发现副拟杆菌(Parabacteroides)具胆酸转化功能,还可产生大量琥珀酸,可激活肠道FXR信号通路,改善脂代谢紊乱,修复肠壁,激活肠道糖异生,从而调节食欲,促进肝脏糖原合成,改善宿主糖代谢紊乱。另外,研究表明副拟杆菌(Parabacteroides)含量降低,会增加机体患肥胖、非酒精性脂肪肝和糖尿病等疾病的倾向。以上结果表明戊糖片球菌CCFM1104在缓解PFOS毒性的基础上,还同时具备调节肠道菌群、调节免疫及肠道屏障、减少肝病、高血压、糖尿病和肥胖的发生。
实施例8:利用本发明戊糖片球菌CCFM1104制备该菌的发酵食品
选用新鲜蔬菜洗净后榨汁,接着进行高温瞬间灭菌,在温度140℃下高温热杀菌2秒后,立即降温至37℃,再接入本发明制备的戊糖片球菌CCFM1104菌剂发酵剂,使其浓度达到106CFU/mL以上,在温度4℃下冷藏保存,于是得到含有本发明戊糖片球菌CCFM1104活菌的果蔬饮料。
利用本发明能够使用戊糖片球菌CCFM1104发酵生产制备其他发酵食品,所述发酵食品包括固态食品、液态食品、半固态食品。所述发酵食品包括乳制品、豆制品、果蔬制品,所述乳制品包括牛奶、酸奶油、干酪;所述果蔬制品包括黄瓜、胡萝卜、甜菜、芹菜、圆白菜制品。
戊糖片球菌CCFM1104在体外对PFOS具有良好的吸附作用;所述戊糖片球菌CCFM1104在清除二苯基三硝基苯肼自由基(DPPH)、清除羟自由基、还原能力中表现出高抗氧化作用;所述戊糖片球菌CCFM1104显著改善因PFOS暴露造成的肝脏肿大;显著降低PFOS暴露后肝脏中TNF-α的含量;所述戊糖片球菌CCFM1104显著降低PFOS暴露后血清中谷丙转氨酶(ALT)、谷草转氨酶(AST)、碱性磷酸酶(ALP)的含量;所述戊糖片球菌CCFM1104升高肝脏中CAT和GSH含量,提高肝脏中抗氧化能力;所述戊糖片球菌CCFM1104能够改善PFOS暴露后的肠道菌群紊乱,降低肠道中S24-7科、乳酸杆菌属(Lactobacillus)、双歧杆菌属(Bifidobacterium)和副拟杆菌属(Parabacteroides)的丰度,降低肝病、便秘、高血压、糖尿病和肥胖的发生倾向。
在PFOS模型小鼠实验中,服用戊糖片球菌CCFM1104能够显著改善因PFOS暴露造成的小鼠肝脏肿大;服用戊糖片球菌CCFM1104能够显著降低PFOS暴露小鼠肝脏中TNF-α的含量;服用戊糖片球菌CCFM1104降低PFOS暴露小鼠血清中ALT、AST、ALP的含量;服用戊糖片球菌CCFM1104升高肝脏中CAT和GSH含量,提高肝脏中抗氧化能力;服用能够改善PFOS暴露小鼠的肠道菌群紊乱,降低肠道中S24-7科、乳酸杆菌属(Lactobacillus)、双歧杆菌属(Bifidobacterium)和副拟杆菌属(Parabacteroides)的丰度,并使肠道菌群趋于正常化,减少肝病、便秘、高血压、糖尿病和肥胖的发生。体外实验表明,戊糖片球菌CCFM1104能够良好的吸附PFOS,能够有效地清除二苯基三硝基苯肼自由基(DPPH)、清除羟自由基、表现出良好的还原能力。
本发明筛选出对PFOS具有高吸附能力且不在人体中定植并且具有高抗氧化能力的益生菌,不仅能够抑制PFOS造成的氧化应激,而且能够从根本上清除人体内的PFOS。戊糖片球菌CCFM1104可用于制备具有缓解PFOS毒性的食品、保健品和药品,具有非常广泛的应用前景。
应说明的是,以上实施例仅用以说明本发明的技术方案而非限制,尽管参照较佳实施例对本发明进行了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的精神和范围,其均应涵盖在本发明的权利要求范围当中。
Claims (4)
1.戊糖片球菌(Pediococcus pentosaceus)CCFM1104,保藏编号为GDMCCNo:60898。
2.一种发酵食品,其特征在于:所述发酵食品为使用权利要求1所述戊糖片球菌CCFM1104发酵生产制得,所述发酵食品包括固态食品、液态食品、半固态食品。
3.如权利要求2所述的发酵食品,其特征在于:所述发酵食品为使用权利要求1所述的戊糖片球菌CCFM1104发酵生产的乳制品、豆制品或果蔬制品,所述乳制品包括牛奶、酸奶油或干酪;所述果蔬制品包括黄瓜、胡萝卜、甜菜、芹菜或圆白菜制品。
4.权利要求1所述的戊糖片球菌CCFM1104在制备缓解PFOS的毒性作用、抗由 PFOS 引起的肝病的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911386349.2A CN110964672B (zh) | 2019-12-29 | 2019-12-29 | 戊糖片球菌ccfm1104、其发酵食品及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911386349.2A CN110964672B (zh) | 2019-12-29 | 2019-12-29 | 戊糖片球菌ccfm1104、其发酵食品及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110964672A CN110964672A (zh) | 2020-04-07 |
CN110964672B true CN110964672B (zh) | 2022-09-02 |
Family
ID=70037026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911386349.2A Active CN110964672B (zh) | 2019-12-29 | 2019-12-29 | 戊糖片球菌ccfm1104、其发酵食品及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110964672B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI770595B (zh) * | 2020-08-27 | 2022-07-11 | 臺灣菸酒股份有限公司 | 乳酸菌用於治療或預防肝臟損傷相關疾病之用途 |
CN113980848B (zh) * | 2021-11-01 | 2023-10-31 | 河北科技大学 | 一种戊糖片球菌sbc5及其应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU745787B2 (en) * | 1997-05-06 | 2002-03-28 | Human Genome Sciences, Inc. | Enterococcus faecalis polynucleotides and polypeptides |
US6617156B1 (en) * | 1997-08-15 | 2003-09-09 | Lynn A. Doucette-Stamm | Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics |
EP2532232A1 (en) * | 2011-06-10 | 2012-12-12 | InterMed Discovery GmbH | Long chain glycolipids useful to avoid perishing or microbial contamination of materials |
CN102559563B (zh) * | 2012-03-05 | 2013-02-20 | 江南大学 | 一种乳酸片球菌ccfm7902及其用途 |
CN111035658A (zh) * | 2018-10-15 | 2020-04-21 | 深圳华大生命科学研究院 | 戊糖片球菌的用途 |
CN111088184B (zh) * | 2019-12-29 | 2021-09-24 | 江南大学 | 多功能屎肠球菌ccfm1106、其饲料添加剂及应用 |
CN111117916B (zh) * | 2019-12-29 | 2021-10-26 | 江南大学 | 缓解pfos毒害作用的多功能戊糖片球菌ccfm1103、其发酵食品及应用 |
CN111117918B (zh) * | 2020-01-06 | 2022-03-25 | 江南大学 | 缓解pfos毒害作用的多功能戊糖片球菌ccfm1107、其发酵食品及应用 |
-
2019
- 2019-12-29 CN CN201911386349.2A patent/CN110964672B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN110964672A (zh) | 2020-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111109359B (zh) | 多功能乳酸片球菌ccfm1105、其发酵食品及应用 | |
Nallu et al. | Gut microbiome in chronic kidney disease: challenges and opportunities | |
Rajilić-Stojanović | Function of the microbiota | |
Huang et al. | The hypocholesterolaemic effects of Lactobacillus acidophilus American Type Culture Collection 4356 in rats are mediated by the down-regulation of Niemann-Pick C1-Like 1 | |
CN110229769B (zh) | 缓解pfoa毒害作用的多功能发酵乳杆菌ccfm1051、其发酵食品及应用 | |
CN111117918B (zh) | 缓解pfos毒害作用的多功能戊糖片球菌ccfm1107、其发酵食品及应用 | |
CN108384735B (zh) | 植物乳杆菌ccfm1019、其发酵食品及其在制备药物中的应用 | |
US20220152130A1 (en) | Multifunctional lactobacillus capable of relieving pfoa toxic effects and application thereof | |
CN110964672B (zh) | 戊糖片球菌ccfm1104、其发酵食品及应用 | |
Zhang et al. | The immunoenhancement effects of sea buckthorn pulp oil in cyclophosphamide-induced immunosuppressed mice | |
Zhu et al. | Preparation and characterization of selenium enriched-Bifidobacterium longum DD98, and its repairing effects on antibiotic-induced intestinal dysbacteriosis in mice | |
CN110226630B (zh) | 缓解pfoa毒害作用的多功能布氏乳杆菌ccfm1053、其发酵食品及应用 | |
Ai et al. | The specific use of alginate from Laminaria japonica by Bacteroides species determined its modulation of the Bacteroides community | |
CN111088184B (zh) | 多功能屎肠球菌ccfm1106、其饲料添加剂及应用 | |
Mu et al. | Lactobacillus plantarum KFY02 enhances the relieving effect of gardenoside on montmorillonite induced constipation in mice | |
Sun et al. | Interaction of sulfated polysaccharides with intestinal Bacteroidales plays an important role in its biological activities | |
Yang et al. | The beneficial effects of polysaccharide obtained from persimmon (Diospyros kaki L.) on the proliferation of Lactobacillus and gut microbiota | |
Huang et al. | Polysaccharides from soybean residue fermented by Neurospora crassa alleviate DSS-induced gut barrier damage and microbiota disturbance in mice | |
Xie et al. | Fecal fermentation and high-fat diet-induced obesity mouse model confirmed exopolysaccharide from Weissella cibaria PFY06 can ameliorate obesity by regulating the gut microbiota | |
Rezaei et al. | Isolation of lactic acid probiotic strains from Iranian camel milk: technological and antioxidant properties | |
Tilwani et al. | Characterization of potential probiotic bacteria Enterococcus faecium MC-5 isolated from the gut content of Cyprinus carpio specularis | |
CN111117916B (zh) | 缓解pfos毒害作用的多功能戊糖片球菌ccfm1103、其发酵食品及应用 | |
CN110684682B (zh) | 缓解pfoa毒害作用的多功能干酪乳杆菌ccfm1052、其发酵食品及应用 | |
Xu et al. | Effects of Rosa roxburghii & edible fungus fermentation broth on immune response and gut microbiota in immunosuppressed mice | |
Qi et al. | Microbiome analysis investigating the impacts of fermented spent mushroom substrates on the composition of microbiota in weaned piglets hindgut |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |